Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This study will examine the effects of add-on sildenafil to bosentan monotherapy in patients
with Pulmonary Arterial Hypertension. Patients on bosentan monotherapy will be followed every
6 months to assess if they have met the pre-defined treatment goals. If a patient fails to
achieve these treatment goals or fails to maintain them, sildenafil will be added to their
existing bosentan monotherapy. Patients will be assessed 6 months after start of combination
therapy for changes in 6MWT, Borg dyspnea scale, WHO functional class, quality of life.